These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 19169706)

  • 21. HER-2/neu in breast cancer: a comparative study between histology, immunohistochemistry, and molecular technique (FISH).
    Rossi E; Ubiali A; Cadei M; Balzarini P; Valagussa E; Lucini L; Alpi F; Galletti A; Fontana L; Tedoldi C; Grigolato P
    Appl Immunohistochem Mol Morphol; 2006 Jun; 14(2):127-31. PubMed ID: 16785778
    [TBL] [Abstract][Full Text] [Related]  

  • 22. SP3, a reliable alternative to HercepTest in determining HER-2/neu status in breast cancer patients.
    D'Alfonso TM; Liu YF; Chen Z; Chen YB; Cimino-Mathews A; Shin SJ
    J Clin Pathol; 2013 May; 66(5):409-14. PubMed ID: 23386665
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Algorithm for the diagnosis of HER-2/neu status in breast-infiltrating carcinomas.
    Falo C; Moreno A; Lloveras B; Figueras A; Varela M; Escobedo A
    Am J Clin Oncol; 2003 Oct; 26(5):465-70. PubMed ID: 14528071
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparative methodological analysis of erbB-2/HER-2 gene dosage, chromosomal copy number and protein overexpression in breast carcinoma tissues for diagnostic use.
    Bánkfalvi A; Simon R; Brandt B; Bürger H; Vollmer I; Dockhorn-Dworniczak B; Lellé RJ; Boecker W
    Histopathology; 2000 Nov; 37(5):411-9. PubMed ID: 11119122
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluation of the United States Food and Drug Administration-approved scoring and test system of HER-2 protein expression in breast cancer.
    Birner P; Oberhuber G; Stani J; Reithofer C; Samonigg H; Hausmaninger H; Kubista E; Kwasny W; Kandioler-Eckersberger D; Gnant M; Jakesz R;
    Clin Cancer Res; 2001 Jun; 7(6):1669-75. PubMed ID: 11410505
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Assessment of HER-2/neu overexpression and/or gene amplification in breast carcinomas: should in situ hybridization be the method of choice?
    Sauer T; Wiedswang G; Boudjema G; Christensen H; Karesen R
    APMIS; 2003 Mar; 111(3):444-50. PubMed ID: 12752225
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A new rabbit monoclonal antibody (4B5) for the immunohistochemical (IHC) determination of the HER2 status in breast cancer: comparison with CB11, fluorescence in situ hybridization (FISH), and interlaboratory reproducibility.
    Powell WC; Hicks DG; Prescott N; Tarr SM; Laniauskas S; Williams T; Short S; Pettay J; Nagle RB; Dabbs DJ; Scott KM; Brown RW; Grogan T; Roche PC; Tubbs RR
    Appl Immunohistochem Mol Morphol; 2007 Mar; 15(1):94-102. PubMed ID: 17536315
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Her-2/neu gene amplification compared with HER-2/neu protein overexpression on ultrasound guided core-needle biopsy specimens of breast carcinoma.
    Kaya H; Ragazzini T; Aribal E; Güney I; Kotiloglu E
    Pathol Oncol Res; 2001; 7(4):279-83. PubMed ID: 11882907
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Specificity of HercepTest in determining HER-2/neu status of breast cancers using the United States Food and Drug Administration-approved scoring system.
    Jacobs TW; Gown AM; Yaziji H; Barnes MJ; Schnitt SJ
    J Clin Oncol; 1999 Jul; 17(7):1983-7. PubMed ID: 10561248
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Accurately assessing her-2/neu status in needle core biopsies of breast cancer patients in the era of neoadjuvant therapy: emerging questions and considerations addressed.
    D'Alfonso T; Liu YF; Monni S; Rosen PP; Shin SJ
    Am J Surg Pathol; 2010 Apr; 34(4):575-81. PubMed ID: 20216378
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Suggestions for HER-2/neu testing in breast carcinoma, based on a comparison of immunohistochemistry and fluorescence in situ hybridisation.
    Field AS; Chamberlain NL; Tran D; Morey AL
    Pathology; 2001 Aug; 33(3):278-82. PubMed ID: 11523924
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Her-2/neu in barrett esophagus: a comparative study between histology, immunohistochemistry, and fluorescence in situ hybridization.
    Rossi E; Villanacci V; Bassotti G; Casa DD; Missale G; Minelli L; Cestari R
    Diagn Mol Pathol; 2006 Sep; 15(3):125-30. PubMed ID: 16932066
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of immunohistochemical and fluorescence in situ hybridization assessment for HER-2/neu status in Taiwanese breast cancer patients.
    Kuo SJ; Wang BB; Chang CS; Chen TH; Yeh KT; Lee DJ; Yin PL; Chen M
    Taiwan J Obstet Gynecol; 2007 Jun; 46(2):146-51. PubMed ID: 17638622
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Validation of a fully automated HER2 staining kit in breast cancer.
    Moelans CB; Kibbelaar RE; van den Heuvel MC; Castigliego D; de Weger RA; van Diest PJ
    Cell Oncol; 2010; 32(1-2):149-55. PubMed ID: 20203372
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of HER2 immunohistochemical results using a monoclonal antibody (SV2-61γ) and a polyclonal antibody (for Dako HercepTest) in advanced gastric cancer.
    Tamura G; Osakabe M; Yanagawa N; Ogata SY; Nomura T; Fukushima N; Ito Y; Tabuchi M
    Pathol Int; 2012 Aug; 62(8):513-7. PubMed ID: 22827758
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of Dako HercepTest and Ventana PATHWAY anti-HER2 (4B5) tests and their correlation with silver
    Miladinović M; Vučković L; Klisic A
    Open Med (Wars); 2021; 16(1):1503-1512. PubMed ID: 34708154
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Her-2/neu gene amplification and protein expression in primary male breast cancer.
    Rudlowski C; Friedrichs N; Faridi A; Füzesi L; Moll R; Bastert G; Rath W; Büttner R
    Breast Cancer Res Treat; 2004 Apr; 84(3):215-23. PubMed ID: 15026619
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Her-2/neu status in breast cancer metastases to the central nervous system.
    Lear-Kaul KC; Yoon HR; Kleinschmidt-DeMasters BK; McGavran L; Singh M
    Arch Pathol Lab Med; 2003 Nov; 127(11):1451-7. PubMed ID: 14567724
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Testing HER2 in breast cancer: a comparative study on BRISH, FISH, and IHC.
    Brügmann A; Lelkaitis G; Nielsen S; Jensen KG; Jensen V
    Appl Immunohistochem Mol Morphol; 2011 May; 19(3):203-11. PubMed ID: 21475037
    [TBL] [Abstract][Full Text] [Related]  

  • 40. IHC for Her2 with CBE356 antibody is a more accurate predictor of Her2 gene amplification by FISH than HercepTest in breast carcinoma.
    Ainsworth R; Bartlett JM; Going JJ; Mallon EA; Forsyth A; Richmond J; Angerson W; Watters A; Dunne B
    J Clin Pathol; 2005 Oct; 58(10):1086-90. PubMed ID: 16189156
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.